Rhythm Pharmaceuticals (RYTM) Gains from Investment Securities (2016 - 2026)
Rhythm Pharmaceuticals (RYTM) reported Gains from Investment Securities of $8.5 million for Q1 2026, up 573.09% year-over-year from $1.3 million in Q1 2025, and up 4259.79% quarter-over-quarter from $194000.0 in Q4 2025.
Rhythm Pharmaceuticals (RYTM) Gains from Investment Securities (2016 - 2026) Analysis & Trends
Rhythm Pharmaceuticals (RYTM) has 11 years of Gains from Investment Securities data on file, last reported at $8.5 million in Q1 2026.
- Gains from Investment Securities for Q1 2026 came in at $8.5 million, up 573.09% year-over-year; the trailing twelve-month figure through Mar 2026 was $10.6 million (up 744.66% YoY), and the FY2025 annual result was -$90000.0, down 186.03% from the prior year.
- Gains from Investment Securities rose to $8.5 million in Q1 2026 per RYTM's latest filing, from $194000.0 in the prior quarter.
- Over five years, Gains from Investment Securities peaked at $8.5 million in Q1 2026 and troughed at -$1.2 million in Q1 2024.
- A 5-year average of $1.6 million and a median of $1.3 million in 2025 frame the typical range for Gains from Investment Securities.
- On a YoY basis, Gains from Investment Securities climbed as much as 78825.0% in 2024 and fell as far as 1307.07% in 2024.
- A 5-year view of Gains from Investment Securities shows it stood at -$1000.0 in 2022, then surged by 500.0% to $4000.0 in 2023, then jumped by 78825.0% to $3.2 million in 2024, then sank by 93.85% to $194000.0 in 2025, then soared by 4259.79% to $8.5 million in 2026.
- Business Quant data shows RYTM's Gains from Investment Securities at $8.5 million in Q1 2026, $194000.0 in Q4 2025, and $3.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Rhythm Pharmaceuticals | 6.59 Bn | 6.25 Bn | 52.96 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 8.46 Mn |
| Mar 31, 2026 | 8.46 Mn |
| Dec 31, 2025 | 194,000.00 |
| Dec 31, 2025 | 194,000.00 |
| Sep 30, 2025 | 3.13 Mn |
| Sep 30, 2025 | 3.13 Mn |
| Jun 30, 2025 | 3.13 Mn |
| Jun 30, 2025 | 3.13 Mn |
| Mar 31, 2025 | 1.26 Mn |
| Mar 31, 2025 | 1.26 Mn |
| Dec 31, 2024 | 3.16 Mn |
| Dec 31, 2024 | 3.16 Mn |
| Sep 30, 2024 | 1.87 Mn |
| Sep 30, 2024 | 1.87 Mn |
| Jun 30, 2024 | 1.89 Mn |
| Jun 30, 2024 | 1.89 Mn |
| Mar 31, 2024 | -1.20 Mn |
| Mar 31, 2024 | -1.20 Mn |
| Dec 31, 2023 | 4,000.00 |
| Dec 31, 2023 | 4,000.00 |